Valuation: Keros Therapeutics, Inc.

Market Cap 225M 200M 187M 170M 321M 21.65B 324M 2.26B 876M 11.07B 846M 827M 35.52B P/E 2026 *
-2.05x
P/E 2027 * -1.82x
Enterprise Value 225M 200M 187M 170M 321M 21.65B 324M 2.26B 876M 11.07B 846M 827M 35.52B EV / Sales 2026 *
14.5x
EV / Sales 2027 * 16.4x
Free-Float
46.49%
Yield 2026 *
-
Yield 2027 * -
1 day+0.89%
1 week-2.24%
Current month-0.35%
1 month+1.16%
3 months+0.89%
6 months-5.33%
Current year-44.20%
1 week 10.92
Extreme 10.925
11.58
1 month 10.7
Extreme 10.7
12.05
Current year 9.69
Extreme 9.69
20.34
1 year 9.69
Extreme 9.69
22.55
3 years 9.12
Extreme 9.12
73
5 years 9.12
Extreme 9.12
73
10 years 9.12
Extreme 9.12
88.8
Manager TitleAgeSince
Chief Executive Officer 70 30/11/2015
Director of Finance/CFO 55 02/08/2026
Chief Tech/Sci/R&D Officer 53 31/05/2019
Director TitleAgeSince
Chairman 70 30/06/2024
Director/Board Member 63 31/03/2016
Director/Board Member 50 29/02/2020
Date Insider Type Main position Quantity % Market Cap. Importance
18/08/26 Sell

Executive/Senior Manager

-3,568 0.0180%
18/08/26 Sell

General Counsel

-4,485 0.0227%
18/08/26 Sell

Chief Financial Officer

-1,224 0.0062%
Change 5-day change 1-year change 3-year change Capi.($)
+0.89%-2.24%-27.09%-63.14% 225M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+21.92%+74.60% 57.39B
+0.89%-0.63%+4.28%+34.51% 47.64B
+0.36%+0.81%+352.17%+689.61% 44.29B
-0.96%-4.50%+26.36%+33.18% 42.5B
-0.20%-0.77%+3.74%+100.60% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.63%+19.50% 28.53B
+0.05%-1.64%-7.28%-14.06% 24.34B
Average -0.11%-0.75%+46.24%+101.94% 39.08B
Weighted average by Cap. +0.12%-0.84%+58.72%+129.80%

Financials

2026 *2027 *
Net sales 15.57M 13.83M 12.91M 11.77M 22.19M 1.5B 22.4M 156M 60.54M 765M 58.45M 57.18M 2.46B 13.73M 12.2M 11.38M 10.37M 19.57M 1.32B 19.75M 138M 53.38M 675M 51.53M 50.42M 2.16B
Net income -110M -98.05M -91.52M -83.41M -157M -10.61B -159M -1.11B -429M -5.42B -414M -405M -17.41B -147M -131M -122M -111M -210M -14.17B -212M -1.48B -573M -7.24B -553M -541M -23.25B
Net Debt - -
Logo Keros Therapeutics, Inc.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Employees
92
Date Price Change Volume
02/10/26 US$11.36 +0.89% 231,533
01/10/26 US$11.26 -1.23% 140,170
30/09/26 US$11.40 +1.88% 131,222
29/09/26 US$11.19 -0.80% 118,350
28/09/26 US$11.28 -2.93% 208,642
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
11.36USD
Average target price
19.83USD
Spread / Average Target
+74.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KROS Stock